[Skip to Content]
[Skip to Content Landing]
December 10, 1982

Human Babesiosis: Clinical and Therapeutic Considerations

Author Affiliations

From the Division of Infectious Diseases, Department of Medicine (Drs Gombert and Goldstein), and the Department of Microbiology and Immunology (Dr Eveland), State University of New York-Downstate Medical Center, Brooklyn; the Infectious Disease Division, Department of Medicine, North Shore University Hospital, Manhasset (Drs Tenenbaum and Kaplan) and Shelter Island (Dr Grunwaldt), NY; and the New York State Department of Health, State University of New York, Stonybrook (Dr Benach).

JAMA. 1982;248(22):3005-3007. doi:10.1001/jama.1982.03330220049035

During a two-month period, six patients from eastern Long Island were identified as having Babesia microti infection. Diagnosis was based on characteristic blood smears, hamster inoculation, or both. Symptom duration ranged from 19 to 24 days in five patients. The sixth patient, who had previously undergone splenectomy, had a more severe and prolonged illness. No specific therapy was administered to five patients. The patient who had had a splenectomy was treated with chloroquine, quinine, pentamidine, and exchange transfusions. There were no deaths. It appears that most cases of human B microti infection can be effectively managed with symptomatic and supportive care.

(JAMA 1982;248:3005-3007)